However, evidences strongly support Rnd3 may act as an anti-oncogene, such as hepatocellular carcinoma [143], squamous cell carcinoma [144], breast cancer [145, 146], prostate cancer [141], colorectal carcinoma [147], and lung cancer [145]. Here, RND3 is linked to prostate carcinoma.